Cingulate Inc

NASDAQ:CINGUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.

Contact Information

Headquarters

1901 W. 47Th PlaceKANSAS CITY, KS, United States 66205

Phone

913-942-2300

Fax

302-636-5454

Executives

Chairman of the Board, Chief Executive Officer, Co-Founder, Principal Financial Officer

Shane Schaffer

Co-Founder, Executive Vice President, Chief Science Officer

Raul Silva

Co-Founder, Executive Vice President, Chief Medical Officer

Matthew Brams

Chief Financial Officer, Senior Vice President, Principal Accounting Officer

Jennifer Callahan

Chief Operating Officer, Executive Vice President

Laurie Myers